Semaglutide sourcing options
Semaglutide pathways, turned into a private sourcing brief for your clinic
Tell us your states, volume and timeline. Your brief is screened against the pharmacy criteria currently on file for compounded semaglutide and you get one of four truthful results. Compounded drugs are not FDA approved; they are patient-specific prescriptions prepared by a licensed pharmacy on a prescriber’s order.
What the review looks at
- Primary operating state and any additional operating states
- Pathway: compounded semaglutide, with any 503A or 503B preference
- Monthly volume band and expected timeline
- Prescription requirements and your current supplier or backup need
Regulatory context, dated and sourced
Compounded semaglutide is prepared as a patient-specific prescription by a licensed 503A pharmacy. Compounded drugs are not FDA approved; FDA does not review them for safety, effectiveness or quality before they are dispensed.
- : FDA page on unapproved GLP-1 drugs: compounding may be appropriate where a patient's medical need cannot be met by an approved drug or the approved drug is not commercially available; 990 adverse-event reports for compounded semaglutide as of 2026-05-31.
- : FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list after a no-clinical-need finding. Not final. 503A patient-specific compounding remains subject to the essentially-a-copy restriction.
Last reviewed 2026-10-11. Not medical advice.
For licensed clinics and prescribers. Do not submit patient or medical information. No pricing, inventory or pharmacy identity is published on this site.
Build your clinic brief
What would you most like to improve?
Choose the closest answer. You can change it later.
From brief to introduction
Requirements first. Introductions second. Decisions stay with the clinic.
How a semaglutide brief moves before any introduction
Your clinic brief
States, program model, expected demand and workflow, in one private brief.
Patient-specific 503A path
Prescription-per-patient orders prepared by a licensed 503A pharmacy.
503B outsourcing path
Weighed against the dated regulatory notes on this page.
State fit
Each operating state is checked against the pathway information on file.
Review
A reviewer checks the fit before any introduction is prepared.
An introduction you choose
Nothing reaches a pharmacy until you accept a specific introduction.
Every operating state is checked on its own
No state is shown as covered here
Before the next sales conversation
Questions to bring into the search
Confirm directly
- Which entity would provide the pharmacy service?
- Which states and clinic models can it support?
- What prescription and patient-specific requirements apply?
- How does onboarding work?
- What fulfillment workflows are supported?
- Which product details and quality documents are available for review?
- What are the current pricing, minimums and payment terms?
- How are shipping, temperature excursions and service issues handled?
- Who owns the ongoing clinic relationship?
Your clinic confirms each answer directly with the provider before making a decision.
Turn the checklist into your clinic brief.
Build my sourcing briefWhat you receive
The private brief, illustrated
Example private brief
Illustrative only; no real pharmacy, price or capacity- Pathway type
- 503A patient-specific compounding (illustrative)
- State fit
- Primary state on file; two additional states to confirm against licensure
- Fulfillment model
- Prescription-per-order; prescriber verification on first order
- Operational requirements
- Written terms, cold-chain shipping conditions, named account contact
- Volume fit
- Stated band sits inside the configured range; ceiling to confirm
- Items requiring confirmation
- Current capacity, licence numbers per state, beyond-use dating
- Questions to ask before accepting an introduction
- Recall history, continuity plan, exit terms, what happens above capacity
A real brief names a specific pharmacy and its terms only after your requirements are reviewed, and only on a private page you open from your own link.
Sources
Where the regulatory notes come from
Sources
- FDA's concerns with unapproved GLP-1 drugs used for weight loss, U.S. Food and Drug Administration ()
Semaglutide sourcing questions
- Will you tell me which pharmacy supplies compounded semaglutide?
- Privately, once a reviewer confirms a fit. A signed private introduction page then names the proposed pharmacy and shows the terms on file before you decide anything. No public page names a pharmacy, and nothing about your clinic reaches the pharmacy until you tick “Introduce me”.
- What is the regulatory status of compounded semaglutide?
- Compounded drugs are not FDA approved; FDA does not review them for safety, effectiveness or quality before they are dispensed. They are patient-specific prescriptions prepared by a licensed pharmacy on a prescriber’s order.
- What does the review assess?
- Your primary and additional operating states, the fulfillment model, your volume band and timeline, and your prescription workflow, against the pharmacy criteria currently configured. If nothing on file applies, you are told so.
- Can I ask for a backup route only?
- Yes. Choose backup sourcing in the brief; the review treats it as a second pathway alongside your current supplier and the backup-sourcing worksheet follows by email.
Looking for tirzepatide instead?
Give your GLP-1 supply search a clearer starting point.
Build one private clinic brief around your states, program and workflow. Review potential pathways without starting every conversation from zero.
For licensed clinics and prescribers. Do not submit patient or medical information.